Literature DB >> 21412144

Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients.

Rajmohan Murali1, Chitra Desilva, John F Thompson, Richard A Scolyer.   

Abstract

BACKGROUND: Studies which have found that histologic features of metastatic melanoma in sentinel lymph nodes (SNs) were predictive of survival have differed considerably in their design and results. We investigated in detail the influence of SN tumor characteristics and clinical and primary tumor parameters on clinical outcomes in a large cohort of patients treated in a single center.
METHODS: In SN-positive melanoma patients, the association of clinical, primary tumor, and SN tumor features [maximum size (MaxSize), % cross-sectional area of SN occupied by tumor (%CS), tumor-penetrative depth (TPD), intranodal location of tumor, extranodal spread (ENS), and perinodal lymphatic invasion (PLI)] with disease-free (DFS), distant metastasis-free (DMFS), and melanoma-specific (MSS) survival was analyzed.
RESULTS: In 409 SN-positive patients, independent predictors of poorer DFS were primary tumor features [anatomic site: head/neck (HR = 3.65, 95% CI 1.65-8.08) and limbs (HR = 2.46, 95% CI 1.21-4.98) compared with trunk; ulceration (HR = 1.70, 95% CI 1.15-2.51); satellites (HR = 2.85, 95% CI 1.49-5.44)], SN tumor features [MaxSize (HR = 1.53, 95% CI 1.04-2.26); ENS in SN (HR = 2.05, 95% CI 1.06-4.00); PLI (HR = 1.85, 95% CI 1.11-3.07)], and positive CLND (HR = 1.92, 95% CI 1.26-2.91). Factors independently predictive of poorer MSS were age ≥50 years (HR 1.64, 95% CI 1.01-2.67), primary tumor features [ulceration (HR = 2.55, 95% CI 1.44-4.52); satellites (HR = 3.95, 95% CI 1.83-8.49)], and ENS in SN (HR = 2.34, 95% CI 1.06-5.13).
CONCLUSIONS: The use of clinical, primary tumor, and SN tumor characteristics shown to be independent predictors of clinical outcomes in melanoma patients will assist in accurate prediction of prognosis and optimize clinical management.

Entities:  

Mesh:

Year:  2011        PMID: 21412144     DOI: 10.1097/SLA.0b013e318214beba

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  8 in total

1.  Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.

Authors:  Sojun Hoshimoto; Tatsushi Shingai; Donald L Morton; Christine Kuo; Mark B Faries; Kelly Chong; David Elashoff; He-Jing Wang; Robert M Elashoff; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

2.  Prediction of sentinel node status and clinical outcome in a melanoma centre.

Authors:  Vera Teixeira; Ricardo Vieira; Inês Coutinho; Rita Cabral; David Serra; Maria José Julião; Maria Manuel Brites; Anabela Albuquerque; João Pedroso de Lima; Américo Figueiredo
Journal:  J Skin Cancer       Date:  2013-12-25

3.  Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR).

Authors:  Richard A Scolyer; Meagan J Judge; Alan Evans; David P Frishberg; Victor G Prieto; John F Thompson; Martin J Trotter; Maureen Y Walsh; Noreen M G Walsh; David W Ellis
Journal:  Am J Surg Pathol       Date:  2013-12       Impact factor: 6.394

4.  Recurrence Rates Over 20 Years in the Treatment of Malignant Melanoma: Immediate Versus Delayed Reconstruction.

Authors:  Pieter G L Koolen; Tiago R Matos; Ahmed M S Ibrahim; Jie Sun; Bernard T Lee; Robert A Frankenthaler; Samuel J Lin
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-07-12

5.  The long-term prognostic impact of sentinel lymph node biopsy in patients with primary cutaneous melanoma: a prospective study with 10-year follow-up.

Authors:  Mattia Portinari; Gabriele Baldini; Massimo Guidoboni; Alessandro Borghi; Stefano Panareo; Simona Bonazza; Gianlorenzo Dionigi; Paolo Carcoforo
Journal:  Ann Surg Treat Res       Date:  2018-10-25       Impact factor: 1.859

6.  Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites?

Authors:  K P Wevers; E Bastiaannet; H P A M Poos; R J van Ginkel; J T Plukker; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2012-05-17       Impact factor: 5.344

7.  Melanoma in the Italian Population and Regional Environmental Influences: A National Retrospective Survey on 2001-2008 Hospitalization Records.

Authors:  Prisco Piscitelli; Cosimo Neglia; Andrea Falco; Matteo Rivezzi; Nadia Agnello; Alberto Argentiero; Giovanna Chitano; Chiara Distante; Giulia Della Rosa; Giorgia Vinci; Antonella De Donno; Alessandro Distante; Antonella Romanini
Journal:  Int J Environ Res Public Health       Date:  2015-08-05       Impact factor: 3.390

8.  Melanoma risk loci as determinants of melanoma recurrence and survival.

Authors:  Justin Rendleman; Shulian Shang; Christine Dominianni; Jerry F Shields; Patrick Scanlon; Christina Adaniel; Alexis Desrichard; Michelle Ma; Richard Shapiro; Russell Berman; Anna Pavlick; David Polsky; Yongzhao Shao; Iman Osman; Tomas Kirchhoff
Journal:  J Transl Med       Date:  2013-11-04       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.